Online inquiry

IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9721MR)

This product GTTS-WQ9721MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&GPRC5D gene. The antibody can be applied in Relapsed multiple myeloma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_018654.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 55507
UniProt ID P07766; Q9NZD1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9721MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ678MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ4291MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ250MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ599MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ5038MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ6421MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ13417MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ11542MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGA031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW